Skip to main content
Premium Trial:

Request an Annual Quote

Mark Bennett Takes Nonlinear to Asia; Arizona Diamondback Pitcher Joins TGen Board; Forlenza Named CEO of BD Biosciences; and Others

NEW YORK, March 19 -- Mark Bennett  has been appointed the new general manager, Asia Pacific, for bioinformatics company Nonlinear Dynamics .


Bennett will fill a position left vacant last year after the death of predecessor Alan Koontz , from a heart attack, last September.  


Bennett has been with Nonlinear , of Newcastle upon Tyne , UK , since 1997, and has served as CEO of Nonlinear USA since its incorporation in 2000. He will retain this title, but will also work to recruit and manage a sales force for the Asia Pacific region, the company said.  Bennett will work particularly in proteomics, where Nonlinear sells data mining tools for 1D and 2D electrophoresis gels.



Curt Schilling , a pitcher for the Arizona Diamondback baseball team in the US , has been appointed to the board of Arizona 's Translational Genomics Research Institute , the institute announced March 18.


Schilling was recruited by TGen president and scientific director Jeffrey Trent , according to the institute.  While he has no background in genomics, he has been involved in fundraising agreements for ALS and melanoma.



Christophe Benoist  and Diane Mathis have been appointed to the scientific advisory board of Phenomix, an in vivo genomic mutation screening company, Phenomix, said March 18.


Benoist and Mathis are both professors of medicine at Harvard Medical School 's Joslin Diabetes Center ,  where they study diseases such as diabetes and rheumatoid arthritis, using transgenic and knockout technology.   They will provide Phenomix with advice on immunological disease research and drug discovery.


Ronald Lindsay  has joined the board of directors of drug discovery informatics company AnVil , of Burlington , Mass, the company said March 17.


Lindsay currently serves as CSO and vice president of R&D at DiaDexus  of San Francisco.  Previously, he was senior vice president of biotherapeutics at Millennium Pharmaceuticals , and vice president R&D of Millennium Biotherapeutics . He has also been vice president of neurobiology of Regeneron Pharmaceuticals and head of cell biology at the Sandoz Institute for Medical Research .


Vincent Forlenza  has been named president of Becton, Dickinson subsidiary BD Biosciences , the company announced March 14.


Forlenza, a 23-year veteran of Becton, Dickinson, has most recently served as senior vice president of technology, strategy, and development for the company. He was also president of BD Diagnostic Systems  for four years.


In his new role, Forlenza will continue to lead BD Technologies, the company said.


He succeeds Deborah Neff , who is leaving BD.  

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.